Related Experiment Video
Updated: May 26, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Therapeutic additions and possible deletions in oncology in 2011
1Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Abstract:
Approval of agents for the treatment of cancers by the US Food and Drug Administration (FDA) was granted to only six new chemical entities in the three years spanning 2008 to 2010. By contrast, in the first nine months of 2011, six new chemical entities were approved for use in cancer. This approval rate is unprecedented and reflects the advances in science since the approval of the first monoclonal antibody (rituximab) in 1997 and the first targeted small-molecule tyrosine kinase inhibitor (imatinib) in 2001 for non-Hodgkin's lymphoma and chronic myelogenous leukemia, respectively. Here we briefly discuss the newly approved agents, a possible deletion from the therapeutic armamentarium, and the use of the FDA accelerated approval process.
Insights
The US Food and Drug Administration (FDA) approved six new cancer agents in 2011, a significant increase reflecting scientific advances. This rapid pace highlights progress in cancer therapeutics and drug approval processes.
Area of Science:
- Oncology
- Pharmacology
- Regulatory Science
Background:
- Cancer treatment approvals by the US Food and Drug Administration (FDA) were limited between 2008-2010.
- Recent scientific advancements have accelerated the development and approval of novel cancer therapies.
Purpose of the Study:
- To discuss newly approved cancer agents.
- To analyze the unprecedented rate of new drug approvals.
- To examine the role of the FDA's accelerated approval process.
Main Methods:
- Review of FDA approval data for cancer agents.
- Historical comparison of approval rates.
- Analysis of key milestones in cancer drug development.
Main Results:
- Six new chemical entities for cancer treatment were approved by the FDA in the first nine months of 2011.
- This approval rate is unprecedented compared to the 2008-2010 period.
- Milestones include the first monoclonal antibody (rituximab) in 1997 and targeted tyrosine kinase inhibitor (imatinib) in 2001.
Conclusions:
- The current pace of cancer drug approval is historically high.
- Advances in targeted therapies and biologics are driving this trend.
- The FDA's accelerated approval pathway plays a crucial role.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

